Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative Analysis

Akiyama, Shintaro; Shimizu, Hiromichi; Tamura, Akiko; Yokoyama, Kaoru; Sakurai, Toshiyuki; Kobayashi, Mariko; Eizuka, Makoto; Yanai, Shunichi; Nomura, Kei; Shibuya, Tomoyoshi; Takahara, Masahiro; Hiraoka, Sakiko; Sako, Minako; Yoshida, Atsushi; Tsuruta, Kozo; Yoshioka, Shinichiro; Koroku, Miki; Omori, Teppei; Saruta, Masayuki; Matsumoto, Takayuki; Okamoto, Ryuichi; Tsuchiya, Kiichiro; Fujii, Toshimitsu

doi:10.1159/000546640

Permalink : https://ousar.lib.okayama-u.ac.jp/71077

ID	71077
フルテキストURL	fulltext.pdf 1.71 MB
著者	Akiyama, Shintaro Department of Gastroenterology, Institute of Medicine, University of Tsukuba Shimizu, Hiromichi Department of Gastroenterology and Hepatology, Institute of Science Tokyo Tamura, Akiko Department of Gastroenterology and Hepatology, Institute of Science Tokyo Yokoyama, Kaoru Department of Gastroenterology, Kitasato University School of Medicine Sakurai, Toshiyuki Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine Kobayashi, Mariko Department of Gastroenterology, Institute of Medicine, University of Tsukuba Eizuka, Makoto Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University Yanai, Shunichi Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University Nomura, Kei Department of Gastroenterology, Juntendo University School of Medicine Shibuya, Tomoyoshi Department of Gastroenterology, Juntendo University School of Medicine Takahara, Masahiro Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Hiraoka, Sakiko Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID publons researchmap Sako, Minako Center for Inflammatory Bowel Disease, Tokyo Yamate Medical Center, Japan Community Healthcare Organization Yoshida, Atsushi Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital Tsuruta, Kozo Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine Yoshioka, Shinichiro Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine Koroku, Miki Institute of Gastroenterology, Tokyo Women’s Medical University Omori, Teppei Institute of Gastroenterology, Tokyo Women’s Medical University Saruta, Masayuki Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine Matsumoto, Takayuki Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University Okamoto, Ryuichi Department of Gastroenterology and Hepatology, Institute of Science Tokyo Tsuchiya, Kiichiro Department of Gastroenterology, Institute of Medicine, University of Tsukuba Fujii, Toshimitsu Department of Gastroenterology and Hepatology, Institute of Science Tokyo
抄録	Introduction: It remains unclear whether Janus kinase (JAK) inhibitors differ in efficacy and safety between elderly and non-elderly patients with ulcerative colitis. Methods: We retrospectively compared outcomes between patients who started a JAK inhibitor at ≥65 years (elderly group) and those <65 years (non-elderly group). Results: Among 228, 215, and 159 patients treated with upadacitinib, filgotinib, and tofacitinib, we identified 14, 36, and 13 elderly patients, respectively. There were no significant differences in efficacy between elderly and non-elderly patients for any of the three JAK inhibitors. The elderly group had a 3-fold higher risk of herpes zoster infection with upadacitinib or tofacitinib compared to the non-elderly group, whereas the risk with filgotinib was less than 3% in both groups. The non-elderly group had a 3-fold higher risk of acne with upadacitinib. Conclusion: Adverse event risks with JAK inhibitors should be considered by age. Given the limitations of this study, including its retrospective design and small sample size, further studies with larger sample sizes are needed to validate our findings.
キーワード	Elderly Janus kinase inhibitors Ulcerative colitis
発行日	2025-06-24
出版物タイトル	Inflammatory Intestinal Diseases
巻	10巻
号	1号
出版者	S. Karger AG
開始ページ	180
終了ページ	186
ISSN	2296-9403
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
著作権者	© 2025 The Author(s).
論文のバージョン	publisher
PubMed ID	40667521
DOI	10.1159/000546640
関連URL	isVersionOf https://doi.org/10.1159/000546640
ライセンス	http://creativecommons.org/licenses/by-nc/4.0
Citation	Shintaro Akiyama, Hiromichi Shimizu, Akiko Tamura, Kaoru Yokoyama, Toshiyuki Sakurai, Mariko Kobayashi, Makoto Eizuka, Shunichi Yanai, Kei Nomura, Tomoyoshi Shibuya, Masahiro Takahara, Sakiko Hiraoka, Minako Sako, Atsushi Yoshida, Kozo Tsuruta, Shinichiro Yoshioka, Miki Koroku, Teppei Omori, Masayuki Saruta, Takayuki Matsumoto, Ryuichi Okamoto, Kiichiro Tsuchiya, Toshimitsu Fujii; Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative Analysis. Inflamm Intest Dis 18 December 2025; 10 (1): 180–186. https://doi.org/10.1159/000546640